Immunic (NASDAQ:IMUX) Coverage Initiated by Analysts at William Blair

Equities researchers at William Blair assumed coverage on shares of Immunic (NASDAQ:IMUX) in a report issued on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating on the stock.

Several other analysts have also commented on IMUX. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. D. Boral Capital restated a “buy” rating and issued a $17.00 target price on shares of Immunic in a research note on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.67.

Immunic Trading Up 1.7 %

Shares of NASDAQ IMUX opened at $1.17 on Tuesday. The firm has a fifty day simple moving average of $1.06 and a two-hundred day simple moving average of $1.22. Immunic has a 12 month low of $0.92 and a 12 month high of $2.11. The firm has a market capitalization of $105.39 million, a PE ratio of -0.95 and a beta of 1.89.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp grew its position in Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after purchasing an additional 11,642 shares during the last quarter. 683 Capital Management LLC grew its holdings in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after buying an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC increased its position in shares of Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after acquiring an additional 22,200 shares in the last quarter. Focus Partners Wealth raised its holdings in Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after acquiring an additional 23,610 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at approximately $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.